Bio-Techne Corp. (TECH) Financial Statements
Historical financial data — 43 statements covering FY2016–FY2025
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein s...
Bio-Techne Corp.'s revenue increased 5.2% year over year, from $1.16B to $1.22B.
Net income decreased 56.3% over the same period, from $168.1M to $73.4M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 144% in total.
Total debt increased by 8.5% to $346.0M.
The debt-to-equity ratio stands at 0.18, indicating a conservative leverage profile.
Operating cash flow declined 3.8% to $287.6M.
Bio-Techne Corp. maintains a moderate net profit margin of 6.0%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $549.5M+98.4% | $78.5M | $361.8M | $93.9M | $142.5M | $2.73B | $447.0M | $1.96B |
| Q3 FY2024 | $853.0M+55.2% | $127.5M | $566.4M | $160.9M | $223.5M | $2.72B | $389.0M | $2.01B |
| Q1 FY2025 | $289.5M-66.1% | $33.6M | $183.0M | $40.0M | $63.9M | $2.74B | $300.0M | $2.14B |
| Q2 FY2025 | $586.5M+102.6% | $68.5M | $376.9M | $87.4M | $148.2M | $2.67B | $300.0M | $2.08B |
| Q3 FY2025 | $902.7M+53.9% | $91.1M | $591.5M | $126.1M | $189.4M | $2.64B | $330.0M | $2.02B |
| Q1 FY2026 | $286.6M-68.3% | $38.2M | $188.1M | $47.7M | $27.6M | $2.53B | $300.0M | $1.97B |
| Q2 FY2026 | $582.4M+103.3% | $76.2M | $379.4M | $102.1M | $110.0M | $2.52B | $260.0M | $2.01B |
| Q3 FY2026 | $893.8M+53.5% | $127.2M | $587.7M | $177.6M | $196.7M | $2.55B | $200.0M | $2.09B |
Balance Sheet Summary (Latest Period)
Total Assets
$2.56B
Total Liabilities
$639.1M
Total Equity
$1.92B
Cash & Equivalents
$162.2M
Total Debt
$346.0M
Current Assets
$608.3M
Current Liabilities
$175.8M
Retained Earnings
$1.07B